| Primary |
| Breast Cancer |
20.5% |
| Plasma Cell Myeloma |
18.2% |
| Multiple Myeloma |
13.6% |
| Osteoporosis |
9.1% |
| Osteogenesis Imperfecta |
6.8% |
| Pain |
6.8% |
| Product Used For Unknown Indication |
6.8% |
| Breast Cancer Metastatic |
4.5% |
| Hypercalcaemia |
4.5% |
| Prostate Cancer |
4.5% |
| Hypercalcaemia Of Malignancy |
2.3% |
| Metastases To Bone |
2.3% |
|
| Osteonecrosis Of Jaw |
31.0% |
| Pain |
13.8% |
| Renal Tubular Atrophy |
6.9% |
| Bone Disorder |
3.4% |
| Hypercalcaemia |
3.4% |
| Neoplasm Progression |
3.4% |
| Normal Newborn |
3.4% |
| Pain In Extremity |
3.4% |
| Proteus Test Positive |
3.4% |
| Purulent Discharge |
3.4% |
| Respiratory Failure |
3.4% |
| Sinusitis |
3.4% |
| Spinal Fracture |
3.4% |
| Subclavian Vein Thrombosis |
3.4% |
| Thrombocytopenia |
3.4% |
| Tooth Loss |
3.4% |
| Toothache |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
21.7% |
| Plasma Cell Myeloma |
14.3% |
| Drug Use For Unknown Indication |
11.2% |
| Breast Cancer |
9.3% |
| Multiple Myeloma |
8.7% |
| Osteoporosis |
8.7% |
| Bone Pain |
3.1% |
| Metastases To Bone |
3.1% |
| Musculoskeletal Disorder |
2.5% |
| Nausea |
2.5% |
| Off Label Use |
2.5% |
| Autoimmune Hepatitis |
1.9% |
| Hypertension |
1.9% |
| Breast Cancer Metastatic |
1.2% |
| Hypercalcaemia |
1.2% |
| Lung Neoplasm Malignant |
1.2% |
| Prophylaxis |
1.2% |
| Renal Cancer |
1.2% |
| Renal Cancer Metastatic |
1.2% |
| Renal Cell Carcinoma |
1.2% |
|
| Osteonecrosis Of Jaw |
56.9% |
| Malaise |
3.9% |
| Metastases To Liver |
3.9% |
| Respiratory Failure |
3.9% |
| Fracture Nonunion |
2.0% |
| Hyponatraemia |
2.0% |
| Intravascular Papillary Endothelial Hyperplasia |
2.0% |
| Metastasis |
2.0% |
| Myelofibrosis |
2.0% |
| Osteolysis |
2.0% |
| Periodontitis |
2.0% |
| Plasma Cell Myeloma |
2.0% |
| Pruritus |
2.0% |
| Purulent Discharge |
2.0% |
| Pyrexia |
2.0% |
| Renal Failure |
2.0% |
| Renal Tubular Atrophy |
2.0% |
| Therapeutic Response Decreased |
2.0% |
| Urinary Tract Infection |
2.0% |
| Uveitis |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
43.9% |
| Plasma Cell Myeloma |
15.6% |
| Drug Use For Unknown Indication |
6.7% |
| Adverse Event |
5.2% |
| Prophylaxis |
4.3% |
| Multiple Myeloma |
3.2% |
| Thrombosis Prophylaxis |
2.9% |
| Pain |
2.7% |
| Constipation |
2.1% |
| Breast Cancer |
1.9% |
| Colorectal Cancer Metastatic |
1.7% |
| Routine Health Maintenance |
1.5% |
| Hypertension |
1.4% |
| Ankylosing Spondylitis |
1.4% |
| Breast Cancer Metastatic |
1.4% |
| Anaemia |
0.9% |
| Atrial Fibrillation |
0.9% |
| Pain In Extremity |
0.9% |
| Urinary Tract Infection |
0.8% |
| Hypercalcaemia |
0.7% |
|
| Plasma Cell Myeloma |
19.7% |
| Pneumonia |
9.1% |
| Death |
7.6% |
| Metastases To Bone |
6.1% |
| Weight Decreased |
6.1% |
| Hypercalcaemia |
4.5% |
| Paraesthesia |
4.5% |
| Renal Failure Acute |
4.5% |
| Squamous Cell Carcinoma Of Skin |
4.5% |
| Breast Cancer |
3.0% |
| Cardiac Failure |
3.0% |
| Ejection Fraction Decreased |
3.0% |
| Myelodysplastic Syndrome |
3.0% |
| Myocardial Infarction |
3.0% |
| Nausea |
3.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.0% |
| Prostate Cancer |
3.0% |
| Pulmonary Embolism |
3.0% |
| Pyrexia |
3.0% |
| Renal Haemorrhage |
3.0% |
|
